Tools / Drugs Naloxone hydrochloride Treats known or suspected opioid overdose. Sold as Narcan, Evzio, Rextovy, Kloxxado, Zimhi and 3 more. Every FDA application for this active ingredient: 10 branded and 80 generic.
As of Nov 22, 2026, FDA lists 90 applications for Naloxone hydrochloride (sold as Narcan, Evzio, Rextovy and others), first approved Apr 13, 1971, with 5 new uses approved and 4 published complete response letters.
Applications : 90 New uses approved : 5 Complete response letters : 4 Medicare spending, 2025 : $7.6M Mechanism of action and target, from ChEMBL Uses, approved and in trials Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
Opiate overdose Approved Substance-related disorders Phase 3 2 trials NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history Approved Application Sponsor Supplements Marketing Apr 13, 1971 Narcan NDA 16636 · New molecular entity ADAPT45 Discontinued Oct 2, 1985 Naloxone ANDA 70188 Wyeth-Ayerst2 Discontinued Oct 2, 1985 Naloxone ANDA 70189 Wyeth-Ayerst3 Discontinued Oct 2, 1985 Naloxone ANDA 70190 Wyeth-Ayerst2 Discontinued Oct 2, 1985 Naloxone ANDA 70191 Wyeth-Ayerst5 Discontinued Oct 22, 1985 Naloxone ANDA 70496 Hikma Pharmaceuticals6 Discontinued Oct 22, 1985 Naloxone ANDA 70298 Hikma Pharmaceuticals10 Discontinued Oct 22, 1985 Naloxone ANDA 70299 Hikma Pharmaceuticals16 Marketed Jan 17, 1986 Naloxone Hydrochloride ANDA 70639 International Medication Systems15 Discontinued Apr 18, 1986 Naloxone Hydrochloride ANDA 70172 Hospira6 Marketed Nov 17, 1986 Naloxone Hydrochloride ANDA 70661 Abraxis Pharmaceuticals0 Discontinued Jan 7, 1987 Naloxone Hydrochloride ANDA 70254 Hospira5 Discontinued Jan 7, 1987 Naloxone Hydrochloride ANDA 70255 Hospira4 Discontinued Jan 7, 1987 Naloxone Hydrochloride ANDA 70256 Hospira6 Marketed Jan 7, 1987 Naloxone Hydrochloride ANDA 70257 Hospira8 Marketed Jan 16, 1987 Naloxone Hydrochloride ANDA 70252 Hospira5 Discontinued Jan 16, 1987 Naloxone Hydrochloride ANDA 70253 Hospira5 Discontinued Mar 24, 1988 Naloxone Hydrochloride ANDA 72076 International Medication Systems15 Marketed May 24, 1988 Naloxone Hydrochloride ANDA 71272 Hikma Pharmaceuticals0 Discontinued May 24, 1988 Naloxone Hydrochloride ANDA 71273 Hikma Pharmaceuticals0 Discontinued May 24, 1988 Naloxone Hydrochloride ANDA 71274 Hikma Pharmaceuticals0 Discontinued May 24, 1988 Naloxone Hydrochloride ANDA 71287 Hikma Pharmaceuticals0 Discontinued Jul 19, 1988 Naloxone Hydrochloride ANDA 71811 Marsam Pharmaceuticals1 Discontinued Jul 28, 1988 Narcan ANDA 71083 Bristol-Myers Squibb0 Discontinued Jul 28, 1988 Narcan ANDA 71084 Bristol-Myers Squibb0 Discontinued Jul 28, 1988 Narcan ANDA 71311 Bristol-Myers Squibb0 Discontinued Jul 29, 2004 Naloxone Hydrochloride ANDA 70171 Hospira4 Discontinued Mar 6, 2014 Naloxone Hydrochloride ANDA 204997 Mylan Institutional0 Marketed Apr 3, 2014 Evzio NDA 205787 · New dosage form, new combination Kaleo3 Discontinued Nov 18, 2015 Narcan NDA 208411 · New dosage form Emergent BioSolutions8 Marketed Jun 29, 2016 Naloxone Hydrochloride ANDA 205014 Mylan Institutional0 Marketed Oct 19, 2016 Evzio NDA 209862 · New formulation or manufacturer Kaleo0 Discontinued Feb 28, 2017 Naloxone Hydrochloride ANDA 208871 Rising Pharmaceuticals2 Marketed Mar 14, 2017 Naloxone Hydrochloride ANDA 208872 Rising Pharmaceuticals1 Marketed Jul 26, 2017 Naloxone Hydrochloride ANDA 207634 Somerset Therapeutics0 Marketed Aug 8, 2017 Naloxone Hydrochloride ANDA 207633 Somerset Therapeutics0 Marketed Dec 17, 2018 Naloxone Hydrochloride ANDA 207846 Chartwell RX1 Discontinued Apr 19, 2019 Naloxone Hydrochloride ANDA 209522 Teva Pharmaceuticals USA3 Marketed Oct 15, 2019 Naloxone Hydrochloride ANDA 212455 Eugia Pharma0 Discontinued Nov 4, 2019 Naloxone Hydrochloride ANDA 212456 Eugia Pharma0 Marketed Jan 17, 2020 Naloxone Hydrochloride ANDA 211286 PH Health0 Discontinued Mar 16, 2020 Naloxone Hydrochloride ANDA 213209 Dr. Reddy's Laboratories1 Marketed Jan 14, 2021 Naloxone Hydrochloride ANDA 213279 Eugia Pharma4 Marketed Jan 29, 2021 Naloxone Hydrochloride ANDA 214785 Baxter Healthcare1 Marketed Apr 29, 2021 Kloxxado NDA 212045 · New formulation or manufacturer Hikma Pharmaceuticals1 Marketed Oct 15, 2021 Zimhi NDA 212854 · New formulation or manufacturer ZMI Pharma0 Marketed Feb 28, 2022 Naloxone Hydrochloride NDA 215457 · New formulation or manufacturer Kaleo1 Discontinued Jun 9, 2022 Naloxone Hydrochloride ANDA 213843 Mylan Laboratories1 Marketed Jun 10, 2022 Naloxone Hydrochloride ANDA 212300 Hikma Pharmaceuticals1 Marketed Jun 21, 2022 Naloxone Hydrochloride ANDA 211951 Padagis Israel1 Marketed Jul 29, 2022 Naloxone Hydrochloride ANDA 215964 PH Health3 Marketed Oct 26, 2022 Naloxone Hydrochloride ANDA 216624 Accord Healthcare2 Marketed Nov 7, 2022 Naloxone Hydrochloride ANDA 214792 Baxter Healthcare0 Marketed Mar 7, 2023 Rextovy NDA 208969 · New formulation or manufacturer Amphastar Pharmaceuticals2 Discontinued Jul 28, 2023 Rivive NDA 217722 · New formulation or manufacturer Harm Reduction Therapeutics0 Marketed Oct 6, 2023 Naloxone Hydrochloride ANDA 216977 BPI Labs1 Marketed Feb 29, 2024 Naloxone Hydrochloride ANDA 218404 Mankind Pharma0 Marketed Apr 2, 2024 Naloxone Hydrochloride ANDA 213573 Fresenius Kabi USA0 Marketed Apr 19, 2024 Rezenopy NDA 215487 · New formulation or manufacturer Scienture1 Marketed Apr 23, 2024 Naloxone Hydrochloride ANDA 217992 Amneal Pharmaceuticals0 Marketed Apr 24, 2025 Naloxone Hydrochloride ANDA 216719 Padagis Israel0 Discontinued Aug 21, 2025 Naloxone Hydrochloride ANDA 214211 Sterinova0 Marketed Aug 18, 2026 Naloxone Hydrochloride ANDA 219942 Sterinova0 Marketed — Naloxone Hydrochloride ANDA 71683 Solopak Laboratories0 Discontinued — Naloxone Hydrochloride ANDA 72089 IGI Laboratories0 Discontinued — Naloxone Hydrochloride ANDA 72090 IGI Laboratories0 Discontinued — Naloxone Hydrochloride ANDA 72091 IGI Laboratories0 Discontinued — Naloxone Hydrochloride ANDA 72092 IGI Laboratories0 Discontinued — Naloxone Hydrochloride ANDA 72093 IGI Laboratories0 Discontinued — Naloxone Hydrochloride ANDA 72115 International Medication Systems0 Discontinued — Naloxone Hcl ANDA 70678 Quad Pharmaceuticals0 Discontinued — Naloxone Hcl ANDA 70679 Quad Pharmaceuticals0 Discontinued — Naloxone Hcl ANDA 70680 Quad Pharmaceuticals0 Discontinued — Naloxone Hydrochloride ANDA 70417 International Medication Systems3 Discontinued — Naloxone Hydrochloride ANDA 70648 Abraxis Pharmaceuticals0 Discontinued — Naloxone Hydrochloride ANDA 70649 Abraxis Pharmaceuticals0 Discontinued — Naloxone Hydrochloride ANDA 71339 Watson Laboratories0 Discontinued — Naloxone Hydrochloride ANDA 71604 Abraxis Pharmaceuticals0 Discontinued — Naloxone Hydrochloride ANDA 71671 Smith & Nephew0 Discontinued — Naloxone Hydrochloride ANDA 71672 Solopak Laboratories0 Discontinued — Naloxone Hydrochloride ANDA 71681 Smith & Nephew0 Discontinued — Naloxone Hydrochloride ANDA 71682 Smith & Nephew0 Discontinued — Naloxone Hydrochloride ANDA 72081 AstraZeneca Pharmaceuticals0 Discontinued — Naloxone Hydrochloride ANDA 72082 IGI Laboratories0 Discontinued — Naloxone Hydrochloride ANDA 72083 IGI Laboratories0 Discontinued — Naloxone Hydrochloride ANDA 72084 IGI Laboratories0 Discontinued — Naloxone Hydrochloride ANDA 72085 IGI Laboratories0 Discontinued — Naloxone Hydrochloride ANDA 72086 IGI Laboratories0 Discontinued — Naloxone Hydrochloride ANDA 72087 IGI Laboratories0 Discontinued — Naloxone Hydrochloride ANDA 72088 IGI Laboratories0 Discontinued
Show all 90Complete response letters FDA's published letters for these applications CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name Product Part Spending, 2025 Change Beneficiaries Naloxone HCl Part D $5.3M −88% 77,307 Kloxxado Part D $1.3M +263% 6,297 Narcan Part D $1.0M −2% 10,657 Rextovy Part D $6K New 128 Naloxone HCL Part B $1K −59% 43 NALOXONE HCL(J2312) Part B under $1K New 23 Zimhi Part D $0 −100% 0
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Naloxone $46.8M for 843,657 prescriptions, −2% on 2024
Narcan $7.7M for 129,139 prescriptions, −41% on 2024
Kloxxado $3.4M for 26,130 prescriptions, +10% on 2024 Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change Naloxone 0.4 mg/mL vial: $3.76 per mL Generic · −10% in a year Naloxone 2 mg/2 mL syringe: $8.86 per mL Generic · −22% in a year Naloxone 4 mg/10 mL vial: $3.76 per mL Generic · −10% in a year Kloxxado 8 mg nasal spray: $59.80 per unit Brand · 0% in a year How its trials ended 58 ClinicalTrials.gov studies testing it, classified by TrialPanorama , partly automatically, so some labels are wrong Of the 14 whose ending is known, 43% met their primary endpoint, 21% missed it and 36% stopped early.
Completed, result not reported 29 50%Completed, result not reported Count29 Share50% Ongoing 9 16%Ongoing Count9 Share16% Met its primary endpoint 6 10%Met its primary endpoint Count6 Share10% Status unknown 6 10%Status unknown Count6 Share10% Stopped: other or unclear 4 7%Stopped: other or unclear Count4 Share7% Missed its primary endpoint 3 5%Missed its primary endpoint Count3 Share5% Stopped: sponsor or business decision 1 2%Stopped: sponsor or business decision Count1 Share2% Trials that missed or stopped early Adverse event reports (FAERS) Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files . A report does not show the drug caused the event.
Cases 1,043
Serious 237 (23%)
Deaths reported 19
By quarter 2025 Q4: 353 · 2026 Q1: 176 · 2026 Q2: 147 · 2026 Q3: 367
Most reported reactions Dental caries (346), Tooth erosion (314), Inappropriate schedule of product administration (248), Wrong technique in product usage process (180), Tooth fracture (132), Toothache (131), Drug withdrawal syndrome (111), Off label use (100), Drug dependence (92), Tooth loss (80) FDA drug safety communications 4 communications since 2020 that name this drug; see all communications Approvals in the EU (EMA) First approved in the EU 559 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals Approvals in Canada (Health Canada) New drug submissions since 1994, matched by ingredient; see all Canadian approvals 104 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all Study Phase Status Posted The Study of Brave-LC LDN Treatment Trial Post-acute COVID-19 Syndrome · National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 Not yet recruiting Nov 4, 2026 Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Opioid Overdose (Trial 3 of 3) Remote vs. In-Person, Remote Visits · State University of New York at Buffalo Not applicable Not yet recruiting Oct 15, 2026 Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder Opioid Use Disorder, Opioid Withdrawal · Clive Michelsen Phase 1 / Phase 2 Not yet recruiting Oct 13, 2026 A Pilot Study on the Efficacy of Oral Low Dose Naltrexone for Vulvodynia Vulvodynia · University of Florida Phase 2 Not yet recruiting Oct 7, 2026 Measurement-Based Care to Support Buprenorphine-Naloxone Treatment in Outpatient Addiction Clinics Opioid Use Disorder · Vanderbilt University Medical Center Not applicable Not yet recruiting Sep 24, 2026 Naloxone for In-Hospital Cardiac Arrest Heart Arrest · Region Skane Phase 2 / Phase 3 Not yet recruiting Sep 8, 2026 A Universal Primary Care Based Intervention to Reduce Youth Overdose Risk Aim 3 Overdose · Boston Medical Center Not applicable Recruiting Sep 1, 2026 Clinician Practice Companion to Address Youth Substance Use Substance Use, Substance-Related Disorders · Massachusetts General Hospital Not applicable Not yet recruiting Jul 24, 2026
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA